key: cord-0785803-5z7krihw
authors: Sgrulletti, Mayla; Ottaviano, Giorgio; Sangerardi, Maria; Chini, Loredana; Dellepiane, Rosa Maria; Martire, Baldassarre; Montin, Davide; Rizzo, Caterina; Moschese, Viviana
title: One step closer to influenza vaccine inclusiveness
date: 2020-11-24
journal: Pediatr Allergy Immunol
DOI: 10.1111/pai.13338
sha: 7f59687d198041c67f5c3f2ef3594e9a2227a622
doc_id: 785803
cord_uid: 5z7krihw

Flu virus infection is a common cause of acute respiratory illness, with the major incidence in pediatric age, high morbidity, and mortality. The flu vaccine is recommended for all people aged ≥6 months, unless specific contraindications are present. Younger and older age, pregnancy, chronic diseases like asthma, and immunodeficiency are risk factors for severe complications following flu infection. Thus, these categories represent the target for flu vaccine strategies in most countries. Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or live‐attenuated influenza virus (LAIV) are currently available, with specific precautions and contraindications. We aim to resume the current indications for vaccines in the vulnerable populations to support flu vaccination inclusiveness, in anticipation of a “universal vaccine” strategy.

contraindications, 3,4 although a "broadly reactive" and "universal" vaccine is desirable for higher effectiveness against circulating seasonal or pandemic strains.

Among children with allergies, asthmatic patients are prone to a more severe clinical course in a flu infection. Flu, as with other respiratory viruses, can be responsible for acute asthma exacerbations (AAE) and a higher rate of hospitalization and admission to the intensive care unit (ICU). 5 Specifically, the risk of hospitalization for children affected by asthma seems to be four-fold higher than for non-asthmatic children. Several studies have shown the effectiveness and safety of both IIV and LAIV in children with asthma, 5 but LAIV is contraindicated in children between 2 and 4 years of age affected by asthma or with history of recurrent wheezing because of reported increase of acute asthma attacks after vaccine administration. 4 In general, it has been reported that the flu vaccine allows a reduction of 59%-78% of AAE with fewer requests for emergency visits and hospitalizations. 6 Among children, egg allergy is frequently reported in patients with asthma. Both IIV and LAIV may contain traces of egg proteins, mainly ovalbumin. Past concerns about the safety of egg-derived influenza vaccines in patients with egg allergy are now outdated. 3, 5 In fact, egg allergy is no longer considered a contraindication to the administration of the influenza vaccine. People with mild allergy reactions (ie, itching) or tolerance to cooked eggs can be regularly vaccinated in the outpatient environment. Only in the case of more severe allergic symptoms such as angioedema, vomiting, respiratory symptoms or anaphylaxis, flu vaccine administration is recommended in a protected environment and should be followed by 60 minutes monitoring. 7 Of note, flu vaccines are contraindicated only in those with a previous severe allergic reaction to other components of flu vaccines (ie, gelatin alpha-gal) or a previous dose of any influenza vaccine. 3 

In pregnant women, the incidence of severe flu-related illness and complications, in both mother and fetus, is significantly higher, particularly during the second and third trimester of gestation. 

Clinical spectrum of recently emerged COVID-19 and influenza infections is very similar. They may both cause respiratory disease, with a variable range of severity from an asymptomatic or mild presentation to severe disease, with a higher risk in vulnerable populations. Also, the impact of co-infection is still unclear. In this scenario, to prevent this vaccine-preventable disease outbreak during COVID-19 pandemic, routine influenza vaccination is recommended for all children of 6 months of age and older, unless specific contraindications are reported by the Referral Center. 11, 12 In conclusion, although current flu vaccines confer protective immunity only against selected matched circulating virus strains, health and economic burden of influenza urges to broaden the implementation of vaccination programs. Further efforts are needed to enhance flu vaccination coverage and inclusiveness for age, health status, and timing, in the expectation of a "universal vaccine". 13

All authors reported no conflicts of interest. 

https://orcid.org/0000-0001-8953-2182

Viviana Moschese https://orcid.org/0000-0001-7650-0632

Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study

The importance of vaccinating children and pregnant women against influenza virus infection

Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices -United States, 2019-20 influenza season

Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children

Influenza burden, prevention, and treatment in asthma-a scoping review by the EAACI Influenza in asthma task force

Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis

Guida alle controindicazioni alle vaccinazioni V edizione. www.salute.gov.it/porta le/docum entaz ione/p6_2_2_1. jsp?lingu a=itali ano&id=2759

Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study

Seasonal influenza vaccine in immunocompromised persons

Vaccination in immunocompromised host: recommendations of Italian Primary Immunodeficiency Network Centers (IPINET). Vaccine

Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region

Consensus statements of the Italian Society of Pediatric Allergy and Immunology for the pragmatic management of children and adolescent with allergic or immunological diseases during the COVID-19 Pandemic

A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases